tranexamic acid has been researched along with Vascular Diseases in 14 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tranexamic acid can reduce bleeding in patients undergoing elective surgery." | 5.14 | Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial. ( McDonald, AH; Strachan, GG; Williams, EW; Williams-Johnson, JA, 2010) |
| "We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, followed by a 1-g infusion over a period of 8 hours after arrival at the hospital) or matched placebo." | 3.30 | Prehospital Tranexamic Acid for Severe Trauma. ( Bernard, SA; Burns, B; Cameron, PA; Dicker, B; Forbes, AB; Gantner, DC; Gruen, RL; Hurford, S; Maegele, M; Martin, CA; Mazur, SM; McArthur, CJ; Medcalf, RL; Mitra, B; Murray, LJ; Myles, PS; Ng, SJ; Pitt, V; Rashford, S; Reade, MC; Swain, AH; Trapani, T; Young, PJ, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 10 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ker, K | 1 |
| Mansukhani, R | 1 |
| Shakur-Still, H | 1 |
| Arribas, M | 1 |
| Beaumont, D | 1 |
| Roberts, I | 1 |
| Gruen, RL | 1 |
| Mitra, B | 1 |
| Bernard, SA | 1 |
| McArthur, CJ | 1 |
| Burns, B | 1 |
| Gantner, DC | 1 |
| Maegele, M | 1 |
| Cameron, PA | 1 |
| Dicker, B | 1 |
| Forbes, AB | 1 |
| Hurford, S | 1 |
| Martin, CA | 1 |
| Mazur, SM | 1 |
| Medcalf, RL | 1 |
| Murray, LJ | 1 |
| Myles, PS | 1 |
| Ng, SJ | 1 |
| Pitt, V | 1 |
| Rashford, S | 1 |
| Reade, MC | 1 |
| Swain, AH | 1 |
| Trapani, T | 1 |
| Young, PJ | 1 |
| Taccone, FS | 1 |
| Citerio, G | 1 |
| Stocchetti, N | 1 |
| Cook, R | 1 |
| Lyon-Maris, J | 1 |
| Martin, R | 1 |
| Solla, DJF | 1 |
| Rubiano, AM | 1 |
| Teixeira, MJ | 1 |
| de Andrade, AF | 1 |
| Paiva, WS | 1 |
| Reynard, C | 1 |
| Berg, PVD | 1 |
| Body, R | 1 |
| Kolias, AG | 1 |
| Horner, D | 1 |
| Menon, DK | 1 |
| Wilson, M | 1 |
| Hutchinson, PJ | 1 |
| Bourn, S | 1 |
| Dodds, N | 1 |
| Schober, P | 1 |
| Mascha, EJ | 1 |
| Loer, SA | 1 |
| Schwarte, LA | 1 |
| Bossers, SM | 1 |
| Goursaud, S | 1 |
| Gaberel, T | 1 |
| Williams-Johnson, JA | 1 |
| McDonald, AH | 1 |
| Strachan, GG | 1 |
| Williams, EW | 1 |
| Iplikcioglu, AC | 1 |
| Berkman, MZ | 1 |
| McCormick, PA | 1 |
| Ooi, H | 1 |
| Crosbie, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: an International Randomised, Double Blind Placebo Controlled Trial[NCT01402882] | Phase 3 | 12,737 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT02753816] | 25 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Study enrollment and goals unable to be reached.) | |||
| A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement[NCT00375258] | Phase 3 | 20,211 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263] | Phase 4 | 150 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries. (NCT02753816)
Timeframe: First burn surgery to hospital discharge
| Intervention | Patients with 1 or more transfusions (Number) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 3 |
To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival. (NCT02753816)
Timeframe: Hospital admission to hospital discharge
| Intervention | Days (Median) |
|---|---|
| Tranexamic Acid | 23 |
| Placebo | 9 |
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries. (NCT02753816)
Timeframe: Intraoperative, average 122 minutes
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 100 |
| Placebo | 325 |
"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3
| Intervention | mls (Mean) |
|---|---|
| Control | 1090 |
| Intraarticular | 716 |
| Systemic | 746 |
Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days
| Intervention | days (Median) |
|---|---|
| Control | 4 |
| Topical | 4 |
| Systemic | 4 |
"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Topical | 1 |
| Systemic | 0 |
Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1
| Intervention | mls (Mean) |
|---|---|
| Control | 1765 |
| Topical | 1613 |
| Systemic | 1807 |
Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| DVT | PE | |
| Control | 0 | 0 |
| Systemic | 0 | 1 |
| Topical | 0 | 2 |
Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 57 | 71 | 75 |
| Systemic | 58 | 72 | 78 |
| Topical | 65 | 75 | 82 |
Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 65 | 76 | 82 |
| Systemic | 68 | 80 | 87 |
| Topical | 74 | 81 | 87 |
1 review available for tranexamic acid and Vascular Diseases
| Article | Year |
|---|---|
Tranexamic acid for gastrointestinal bleeding: can a reduction in the risk of death be discounted? A systematic review and meta-analysis of individual patient data from 64 724 bleeding patients.
Topics: Antifibrinolytic Agents; Female; Gastrointestinal Hemorrhage; Humans; Pregnancy; Tranexamic Acid; Va | 2023 |
3 trials available for tranexamic acid and Vascular Diseases
| Article | Year |
|---|---|
Prehospital Tranexamic Acid for Severe Trauma.
Topics: Adult; Antifibrinolytic Agents; Australia; Blood Coagulation Disorders; Emergency Medical Services; | 2023 |
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Injuries, Traumatic; Drug Administration Schedule; Femal | 2019 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
10 other studies available for tranexamic acid and Vascular Diseases
| Article | Year |
|---|---|
Is tranexamic acid going to CRASH the management of traumatic brain injury?
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid is safe to use following mild-to-moderate traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Technology Assessment, Biomedical; Trane | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
The effect of short-term antifibrinolytic therapy on experimental vasospasm.
Topics: Animals; Antifibrinolytic Agents; Femoral Artery; Male; Microscopy, Electron; Rats; Rats, Sprague-Da | 2003 |
Tranexamic acid for severe bleeding gastric antral vascular ectasia in cirrhosis.
Topics: Aged; Antifibrinolytic Agents; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Stomach | 1998 |